Reversible Posterior Encephalopathy Syndrome Secondary to Sunitinib

Table 1

Reports of reverse posterior leukoencephalopathy syndrome associated with sunitinib.

Case author	Age (years)/gender	Onset after starting sunitinib	Management	Recovery after discontinuation
Padhy et al. [11]	65/male	8 days	Sunitinib discontinuation, antihypertensive	Complete recovery in 17 days
Kapiteijn et al. [12]	54/female	8 months	Sunitinib discontinuation, antihypertensive, anticonvulsants	Complete recovery in 10 days
Martín et al. [13]	70/female	2 weeks	Sunitinib discontinuation, antihypertensive, anticonvulsants	Complete recovery in few days
Cumurciuc et al. [14]	39/female	1 week	Sunitinib discontinuation, antihypertensive, anticonvulsants	Complete recovery in 2 weeks
Chen and Agarwal [15]	48/female	1 week	Sunitinib discontinuation	Complete recovery in 3 weeks
van der veldt et al. [16]	84/female	14 days	sunitinib discontinuation	Complete recovery in 3 days
van der veldt et al. [16]	74/male	13 days	sunitinib discontinuation	Complete recovery in 3 days
Hadj et al. [17]	61/male	15 weeks	Sunitinib discontinuation, antihypertensive, anticonvulsants	Complete recovery in 10 weeks
Present case	67/male	2 months	Sunitinib discontinuation, antihypertensive, anticonvulsants	Complete recovery not achieved (patient deceased few weeks after discontinuation of sunitinib due to cancer progression)